The First Molecular Profiling of JAK2 Exon 12 and Flanking Intronic Sequences in Indonesia.

Q2 Medicine
Farmaditya Eka Putra Mundhofir, Nani Maharani, Raisa Tahira, Amelia Syabani, Nydia Rena Benita Sihombing, Ferdy Kurniawan Cayami, Endang Mahati, Tri Indah Winarni
{"title":"The First Molecular Profiling of JAK2 Exon 12 and Flanking Intronic Sequences in Indonesia.","authors":"Farmaditya Eka Putra Mundhofir, Nani Maharani, Raisa Tahira, Amelia Syabani, Nydia Rena Benita Sihombing, Ferdy Kurniawan Cayami, Endang Mahati, Tri Indah Winarni","doi":"10.31557/APJCP.2026.27.9.3237","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Data on JAK2 Exon 12 mutations in Indonesia are not available. This study aimed to explore the presence of known JAK2 exon 12 coding mutations in V617F-negative myeloproliferative neoplasm (MPN) patients in Indonesia and to describe any novel intronic changes downstream of exon 12.</p><p><strong>Methods: </strong>A total of 198 V617F-negative MPN samples were screened using allele-specific polymerase chain reaction (AS-PCR) for four commonly reported canonical exon 12 mutations. Of these, 57 cases were selected at random or for atypical PCR band patterns and underwent bidirectional Sanger sequencing of a 496-bp fragment covering exon 12 plus ~250 bp of the adjacent region. Variants were cross-referenced with gnomAD v4.1.0. Furthermore, SpliceAI was used to predict splice site gain or loss.</p><p><strong>Results: </strong>No coding mutations were identified in exon 12. However, two intronic variants were detected adjacently downstream: NC_000009.12:g.5070231_5070235delTCTTA in 29 of 57 cases (50.9%), which was not present in the gnomAD database, and NC_000009.12:g.5070319C>T in 1 of 57 cases (1.8%), corresponding to a rare gnomAD entry. The SpliceAI Δ scores remained below 0.2, a high-sensitivity threshold, indicating no predicted impact on canonical splicing.</p><p><strong>Conclusion: </strong>Classic exon 12 coding mutations are apparently absent in Indonesian V617F-negative MPNs. We report a highly frequent downstream intronic deletion not recorded in global databases, as well as a rare single nucleotide variant (SNV) that aligns with gnomAD data. Although in silico tools suggest minimal splice disruption, RNA-level assays are needed to rule out the subtle effects of the variant. Our workflow, which combines allele-specific PCR and targeted sequencing, may be suitable for laboratories facing resource constraints.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3237-3243"},"PeriodicalIF":0.0000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2026.27.9.3237","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Data on JAK2 Exon 12 mutations in Indonesia are not available. This study aimed to explore the presence of known JAK2 exon 12 coding mutations in V617F-negative myeloproliferative neoplasm (MPN) patients in Indonesia and to describe any novel intronic changes downstream of exon 12.

Methods: A total of 198 V617F-negative MPN samples were screened using allele-specific polymerase chain reaction (AS-PCR) for four commonly reported canonical exon 12 mutations. Of these, 57 cases were selected at random or for atypical PCR band patterns and underwent bidirectional Sanger sequencing of a 496-bp fragment covering exon 12 plus ~250 bp of the adjacent region. Variants were cross-referenced with gnomAD v4.1.0. Furthermore, SpliceAI was used to predict splice site gain or loss.

Results: No coding mutations were identified in exon 12. However, two intronic variants were detected adjacently downstream: NC_000009.12:g.5070231_5070235delTCTTA in 29 of 57 cases (50.9%), which was not present in the gnomAD database, and NC_000009.12:g.5070319C>T in 1 of 57 cases (1.8%), corresponding to a rare gnomAD entry. The SpliceAI Δ scores remained below 0.2, a high-sensitivity threshold, indicating no predicted impact on canonical splicing.

Conclusion: Classic exon 12 coding mutations are apparently absent in Indonesian V617F-negative MPNs. We report a highly frequent downstream intronic deletion not recorded in global databases, as well as a rare single nucleotide variant (SNV) that aligns with gnomAD data. Although in silico tools suggest minimal splice disruption, RNA-level assays are needed to rule out the subtle effects of the variant. Our workflow, which combines allele-specific PCR and targeted sequencing, may be suitable for laboratories facing resource constraints.

印度尼西亚JAK2 12外显子和侧翼内含子序列的首次分子分析。
目的:印度尼西亚没有JAK2外显子12突变的数据。本研究旨在探索印度尼西亚v617f阴性骨髓增殖性肿瘤(MPN)患者中已知JAK2外显子12编码突变的存在,并描述外显子12下游的任何新的内含子变化。方法:采用等位基因特异性聚合酶链反应(AS-PCR)对198份v617f阴性的MPN样本进行4种常见外显子12突变的筛选。其中,随机选择57例或非典型PCR带型,对覆盖12外显子的496 bp片段和邻近区域的约250 bp进行双向Sanger测序。变体与gnomAD v4.1.0交叉引用。此外,SpliceAI用于预测剪接位点的增加或减少。结果:12外显子未发现编码突变。然而,相邻下游检测到两个内含子变异:NC_000009.12:g。5070231_5070235delTCTTA在57例中有29例(50.9%),在gnomAD数据库中不存在;5070319C>T在57例中的1例(1.8%),对应于一个罕见的gnomAD条目。SpliceAI Δ得分仍然低于0.2,这是一个高灵敏度阈值,表明对典型剪接没有预测影响。结论:印尼v617f阴性mpn中明显不存在经典的外显子12编码突变。我们报告了一个高度频繁的下游内含子缺失,没有记录在全球数据库中,以及一个罕见的单核苷酸变异(SNV),与gnomAD数据一致。虽然在硅工具显示最小剪接中断,rna水平的分析需要排除微妙的影响的变异。我们的工作流程结合了等位基因特异性PCR和靶向测序,可能适合面临资源限制的实验室。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
779
审稿时长
3 months
期刊介绍: Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书